Wall Street analyst estimates for Liquidia Corporation (LQDA): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension.
Consensus price target
$72.36 (+53% vs price $47.38)
between $33.00 and $130.00 · 11 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $717M | $645M – $789M | $2.03 | 6 |
| 2027E | $762M | $540M – $985M | $2.19 | 5 |
| 2028E | $886M | $720M – $1.0B | $3.30 | 5 |
Figures in USD · consensus as of November 3, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (−2 sell to +2 buy) | 0.56 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $0.96 | ||
| 2026-08-12 | $0.74 | $0.70 | +5.7% |
| 2026-05-11 | $0.52 | $0.34 | +52.9% |
| 2026-03-05 | $0.15 | $0.08 | +87.5% |
| 2025-11-03 | $-0.04 | $-0.45 | +91.1% |
| 2025-08-12 | $-0.49 | $-0.43 | -14.0% |
| 2025-05-08 | $-0.45 | $-0.42 | -7.1% |
| 2025-03-19 | $-0.46 | $-0.38 | -21.1% |
Valuation Ratios
| P/E Ratio | 34.61 |
| Price / Book | 21.58 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2M | $7.3M | $2.7M | $8.1M | $739,628 | $12.9M | $15.9M | $17.5M | $14.0M | $158.3M |
| Cost of Revenue | $918,778 | $319,759 | $121,391 | $807,192 | $237,712 | $3.0M | $2.9M | $2.9M | $5.9M | $13.2M |
| Gross Profit | $12.3M | $6.9M | $2.6M | $7.3M | $501,916 | $9.8M | $13.1M | $14.6M | $8.1M | $145.1M |
| Research & Development | $23.3M | $24.8M | $28.7M | $40.5M | $32.2M | $20.5M | $19.4M | $43.2M | $47.8M | $39.3M |
| Selling, General & Admin | $4.8M | $10.2M | $8.8M | $13.6M | $27.4M | $23.1M | $32.4M | $44.7M | $81.6M | $157.2M |
| Operating Expenses | $28.2M | $35.0M | $37.5M | $54.1M | $59.6M | $43.6M | $51.8M | $88.0M | $129.4M | $196.5M |
| Operating Income | -$15.9M | -$28.0M | -$34.9M | -$46.8M | -$59.1M | -$33.8M | -$38.8M | -$73.4M | -$121.3M | -$51.4M |
| EBITDA | -$15.2M | -$15.2M | -$32.6M | -$43.6M | -$55.8M | -$28.2M | -$35.0M | -$70.1M | -$115.7M | -$43.2M |
| Interest Expense | $85,865 | $13.0M | $19.0M | $1.4M | $857,998 | $762,000 | $2.3M | $6.3M | $12.5M | $24.2M |
| Pre-tax Income | -$15.9M | -$29.2M | -$53.1M | -$47.6M | -$59.8M | -$34.6M | -$41.0M | -$78.5M | -$130.4M | -$68.9M |
| Income Tax | $14,906 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$15.9M | -$29.2M | -$53.1M | -$47.6M | -$59.8M | -$34.6M | -$41.0M | -$78.5M | -$130.4M | -$68.9M |
| EPS | -$1.86 | -$3.40 | -$7.42 | -$2.51 | -$1.76 | -$0.70 | -$0.67 | -$1.21 | -$1.66 | -$0.80 |
| EPS (Diluted) | -$1.86 | -$3.40 | -$7.42 | -$2.51 | -$1.76 | -$0.70 | -$0.67 | -$1.21 | -$1.66 | -$0.80 |
| Shares Outstanding (Diluted) | 8.6 M | 8.6 M | 7.2 M | 18.5 M | 33.9 M | 49.7 M | 61.0 M | 65.0 M | 78.7 M | 86.1 M |
Price
| Price | $47.38 (closing price, November 4, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: INSM · UTHR · RPRX · 0I3Q.L · CORT · KNSA · 0HF9.L · PBH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of LQDA: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks